Cerus (CERS) Should Benefit From FDA Revised Zika Guidance - FBR
- Wall Street falls as bank, healthcare shares weigh
- Qualcomm (QCOM) Faces U.S. Antitrust Case Over Licensing - Bloomberg
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
FBR Capital analyst, Thomas Yip, reiterated his Outperform rating on shares of Cerus (NASDAQ: CERS) after the FDA issued revised industry guidance last Friday (August 26, 2016) for reducing the risk of Zika virus (ZIKV) transmission. The analyst thinks that the agency's tightening requirements for blood providers in response to a potential ZIKV outbreak are likely to evolve into a higher safety standard for the industry in the long run.
The primary objective of the revised guidance is to safeguard whole blood and individual blood components collected in all U.S. states and U.S. territories against ZIKV in the immediate time frame. However, he thinks the speed of implementation mandated for blood providers signals the FDA's increasing emphasis on safeguarding the U.S. blood supply at the point of collection, could lead to increased INTERCEPT adoption in a longer time horizon.
No change to the price target of $10.00
Shares of Cerus closed at $6.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: JPMorgan Downgrades OneMain (OMF) to Neutral
- Wedbush Cuts Price Target on GameStop (GME) to $28; Reiterates Outperform
- Needham & Company Raises Price Target on Cornerstone OnDemand (CSOD) Following Industry Checks
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!